OTCPK:IGMB

Stock Analysis Report

Executive Summary

iGambit Inc., through its subsidiary, focuses on the medical technology markets.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Risks

  • iGambit has significant price volatility in the past 3 months.
  • iGambit is not covered by any analysts.

Share Price & News

How has iGambit's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-22.2%

IGMB

0.9%

US Healthcare Services

-0.2%

US Market


1 Year Return

-78.0%

IGMB

8.7%

US Healthcare Services

1.1%

US Market

IGMB underperformed the Healthcare Services industry which returned 8.7% over the past year.

IGMB underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

IGMBIndustryMarket
7 Day-22.2%0.9%-0.2%
30 Day-30.0%-5.2%2.5%
90 Day-22.2%-5.5%1.6%
1 Year-78.0%-78.0%8.8%8.7%3.4%1.1%
3 Year-96.8%-96.8%49.7%49.4%45.2%35.8%
5 Year-81.6%-81.6%50.3%49.4%62.6%44.8%

Price Volatility Vs. Market

How volatile is iGambit's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is iGambit undervalued based on future cash flows and its price relative to the stock market?

1.34x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for iGambit to establish if it is available at moderate discount.

Unable to calculate intrinsic value for iGambit to establish if it is available at substantial discount.


Price Based on Earnings

iGambit is loss making, we can't compare its value to the US Healthcare Services industry average.

iGambit is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for iGambit, we can't assess if its growth is good value.


Price Based on Value of Assets

iGambit is good value based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is iGambit expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iGambit has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of IGMB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access iGambit's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has iGambit performed over the past 5 years?

-45.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

iGambit does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare iGambit's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare iGambit's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if iGambit has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if iGambit has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if iGambit improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is iGambit's financial position?


Financial Position Analysis

iGambit's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

iGambit has no long term commitments.


Debt to Equity History and Analysis

iGambit's level of debt (63.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.8% vs 63.8% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

iGambit has less than a year of cash runway based on current free cash flow.

iGambit has less than a year of cash runway if free cash flow continues to grow at historical rates of 47.2% each year.


Next Steps

Dividend

What is iGambit's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate iGambit's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate iGambit's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as iGambit has not reported any payouts.

Unable to verify if iGambit's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as iGambit has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of iGambit's salary, the management and board of directors tenure and is there insider trading?

10.1yrs

Average board tenure


CEO

John Salerno (81yo)

0yrs

Tenure

US$97,649

Compensation

Mr. John Salerno serves as Chief Executive Officer and President of iGAMBIT, Inc. Mr. Salerno served as the Interim Chief Executive Officer and President of iGAMBIT, Inc. since October 24, 2016 and served  ...


CEO Compensation Analysis

John's remuneration is lower than average for companies of similar size in United States of America.

John's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

10.1yrs

Average Tenure

68yo

Average Age

The average tenure for the iGambit board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • James Charles (76yo)

    • Tenure: 0yrs
    • Compensation: US$4.00k
  • John Salerno (81yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: US$97.65k
  • Elisa Luqman (55yo)

    CFO, Executive VP

    • Tenure: 10.1yrs
    • Compensation: US$140.04k
  • Jerry Robinson

    President of HealthDatix

    • Tenure: 0yrs
    • Compensation: US$69.39k
  • Kathleen Shepherd

    Chief Technology Offocet of HealthDatix

    • Tenure: 0yrs
    • Compensation: US$69.38k
  • MaryJo Robinson

    Executive Vice President of HealthDatix

    • Tenure: 0yrs
    • Compensation: US$68.36k

Board Members

  • John Salerno (81yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: US$97.65k
  • Benedict Maniscalco (77yo)

    Chairman of Advisory Board

    • Tenure: 0yrs
  • Rob Randelman (59yo)

    Member of Senior Advisory Board

    • Tenure: 2.3yrs
  • Elisa Luqman (55yo)

    CFO, Executive VP

    • Tenure: 10.1yrs
    • Compensation: US$140.04k
  • Alan Lezzi

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

iGambit Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iGambit Inc.
  • Ticker: IGMB
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$1.360m
  • Shares outstanding: 388.55m
  • Website: https://www.igambit.com

Number of Employees


Location

  • iGambit Inc.
  • 1050 West Jericho Turnpike
  • Suite A
  • Smithtown
  • New York
  • 11787
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IGMBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2011

Biography

iGambit Inc., through its subsidiary, focuses on the medical technology markets. The company offers end software-as-a-service solution that manages, reports, and analyzes critical data to healthcare and co ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:25
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.